Jane Street Group LLC Purchases 79,222 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Jane Street Group LLC lifted its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 58.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 214,027 shares of the biopharmaceutical company's stock after buying an additional 79,222 shares during the period. Jane Street Group LLC owned about 0.38% of Agios Pharmaceuticals worth $7,033,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in AGIO. Venturi Wealth Management LLC bought a new stake in shares of Agios Pharmaceuticals during the fourth quarter worth $33,000. Wingate Wealth Advisors Inc. bought a new position in Agios Pharmaceuticals during the 4th quarter worth about $53,000. Sterling Capital Management LLC raised its stake in shares of Agios Pharmaceuticals by 818.0% in the 4th quarter. Sterling Capital Management LLC now owns 1,781 shares of the biopharmaceutical company's stock valued at $59,000 after purchasing an additional 1,587 shares during the period. KBC Group NV raised its stake in shares of Agios Pharmaceuticals by 30.5% in the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 611 shares during the period. Finally, AlphaQuest LLC lifted its holdings in shares of Agios Pharmaceuticals by 106.2% in the fourth quarter. AlphaQuest LLC now owns 4,540 shares of the biopharmaceutical company's stock valued at $149,000 after purchasing an additional 2,338 shares in the last quarter.

Agios Pharmaceuticals Stock Performance

Agios Pharmaceuticals stock traded down $0.72 during midday trading on Friday, reaching $27.32. 303,182 shares of the company's stock were exchanged, compared to its average volume of 697,008. The stock's 50-day simple moving average is $29.23 and its 200 day simple moving average is $37.17. The firm has a market cap of $1.58 billion, a price-to-earnings ratio of 2.41 and a beta of 0.77. Agios Pharmaceuticals, Inc. has a 52 week low of $23.42 and a 52 week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The business had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.86 million. Research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

AGIO has been the topic of several research reports. StockNews.com upgraded Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Saturday. HC Wainwright began coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They set a "buy" rating and a $58.00 target price for the company. Finally, Scotiabank lowered their price target on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating on the stock in a research note on Friday, May 2nd. Five research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $56.00.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the stock in a transaction on Thursday, April 10th. The stock was sold at an average price of $25.90, for a total transaction of $194,172.30. Following the transaction, the director now owns 149,220 shares in the company, valued at $3,864,798. This trade represents a 4.78 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 4.93% of the company's stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.